Material Fact - Business Combination between GNDI and Hapvida: Consummation of the Business Combination

PÚBLICO

NOTRE DAME INTERMÉDICA	HAPVIDA PARTICIPAÇÕES E
PARTICIPAÇÕES S.A.	INVESTIMENTOS S.A.
CNPJ 19.853.511/0001-84	CNPJ 05.197.443/0001-38
Publicly-held company	Publicly-held company

MATERIAL FACT

CONSUMMATION OF THE BUSINESS COMBINATION

BETWEEN GNDI AND HAPVIDA

Notre Dame Intermédica Participações S.A. (B3: GNDI3) (GNDI) and Hapvida

Participações e Investimentos S.A. (B3: HAPV3) (Hapvida and, jointly with GNDI, the Companies), in addition to the Material Facts and Notices to the Market disclosed with respect the business combination between GNDI and Hapvida (Transaction), inform their respective shareholders and the market in general that, on this date, the Transaction was consummated and became effective, as confirmed by the respective boards of directors of the Companies in meetings held on this date, pursuant to the "Protocol and Justification of Merger of Shares Issued by Notre Dame Intermédica Participações S.A. into Hapvida Participações e Investimentos II S.A., followed by Merger of Hapvida Participações e Investimentos II S.A. into Hapvida Participações e Investimentos S.A.", entered into on February 27, 2021 (Protocol and Justification), approved at the extraordinary general meetings of GNDI and Hapvida held on March 29, 2021.

As informed in the Notice to the Market disclosed on January 20, 2022 by the Companies, today was the final trading day of GNDI's shares at B3 under the ticker GNDI3. The holders of GNDI shares at the closing of the trading session on this date will be considered as shareholders of GNDI, both for the purposes of the Transaction and to be entitled to receive the extraordinary dividends declared by GNDI on January 20, 2022 (Extraordinary Dividends).

Pursuant to the abovementioned Notice to the Market, on February 14, 2022, the trading of the new Hapvida common shares that will be issued to GNDI shareholders will begin, based on the exchange ratio of 5.24364185943 Hapvida common shares for each common share issued by GNDI. The effective credit of the new Hapvida shares will occur on February 16, 2022. The Final Exchange Ratio already considers all the adjustments provided for in the Protocol and Justification, and disregards GNDI's treasury shares.

In addition, pursuant to the Notice to the Market disclosed on February 9, 2022, the final value to be received by GNDI shareholders in consideration for the redemption of the redeemable preferred shares of HapvidaCo shall be of R$5.16614751932 for each GNDI common share owned (Final Cash Portion). The Final Cash Portion already

PÚBLICO

PÚBLICO

considers all the adjustments provided for in the Protocol and Justification, as well as the adjustment by the variation of the CDI over the total amount of R$4,000,000,000.00 as of March 29, 2021 (exclusive) until this date (inclusive).

Finally, the shareholders of GNDI on this date shall also be entitled to receive the Extraordinary Dividends declared by GNDI on January 20, 2022, in the gross amount of R$ 1.613026961 for each GNDI share.

The payment of the Final Cash Portion and of the Extraordinary Dividends will be made on March 29, 2022.

The amounts mentioned herein are gross and shall be subject to potential tax impacts on the payment to resident or non-resident shareholders of GNDI, as indicated in the notice to the market disclosed on January 20, 2022.

Hapvida will inform in due course the procedures related to the auction and payment of the eventual fractions of shares resulting from the consummation of the Transaction.

São Paulo, SP, February 11, 2022	Fortaleza, CE, February 11, 2022
Glauco Desiderio	Mauricio Teixeira
Investors Relations Officer	CFO and Investor Relations Officer

PÚBLICO